These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35676450)

  • 1. Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
    Li J; Xue Z; Wu Z; Bi L; Liu H; Wu L; Liu S; Huang X; Wang Y; Zhang Y; Qi W; He L; Dai L; Sun L; Li X; Shuai Z; Zhao Y; Wang Y; Xu J; Zhang H; Yu H; Chen X; Bao C
    Clin Rheumatol; 2022 Oct; 41(10):3005-3016. PubMed ID: 35676450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    BioDrugs; 2020 Jun; 34(3):381-393. PubMed ID: 32078145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.
    Xu H; Li Z; Wu J; Xing Q; Shi G; Li J; Liu X; Wu L; Li X; Tan W; He D; Bi L; Li H; Xiao Z; Shuai Z; Li X; Wang Y; Luo L; Zheng Y; Xiao W; Wu X; Zhou L; Li T; Qian L; Zhou H; Lu S; Zheng S; Xiong Y; Wang X; Wang Y; Wu X
    Lancet Rheumatol; 2019 Sep; 1(1):e35-e43. PubMed ID: 38229357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of adalimumab in Chinese adults with active ankylosing spondylitis: results of a randomised, controlled trial.
    Huang F; Gu J; Zhu P; Bao C; Xu J; Xu H; Wu H; Wang G; Shi Q; Andhivarothai N; Anderson J; Pangan AL
    Ann Rheum Dis; 2014 Mar; 73(3):587-94. PubMed ID: 23475983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study.
    Cai L; Li L; Cheng H; Ding Y; Biao Z; Zhang S; Geng S; Liu Q; Fang H; Song Z; Lu Y; Li S; Guo Q; Tao J; He L; Gu J; Yang Q; Han X; Gao X; Deng D; Li S; Wang Q; Zhu J; Zhang J
    Adv Ther; 2022 Jan; 39(1):583-597. PubMed ID: 34816373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    van der Heijde D; Kivitz A; Schiff MH; Sieper J; Dijkmans BA; Braun J; Dougados M; Reveille JD; Wong RL; Kupper H; Davis JC;
    Arthritis Rheum; 2006 Jul; 54(7):2136-46. PubMed ID: 16802350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.
    Kobayashi S; Harigai M; Mozaffarian N; Pangan AL; Sharma S; Brown LS; Miyasaka N
    Mod Rheumatol; 2012 Aug; 22(4):589-97. PubMed ID: 22205117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement.
    Horneff G; Fitter S; Foeldvari I; Minden K; Kuemmerle-Deschner J; Tzaribacev N; Thon A; Borte M; Ganser G; Trauzeddel R; Huppertz HI
    Arthritis Res Ther; 2012 Oct; 14(5):R230. PubMed ID: 23095307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects.
    Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adalimumab biosimilar candidate (HS016) in Chinese patients with active ankylosing spondylitis based on a health survey: sub-analysis of a phase 3 study.
    Su J; Li M; He L; Zhao D; Wan W; Liu Y; Xu J; Xu J; Liu H; Jiang L; Wu H; Zuo X; Huang C; Liu X; Li F; Zhang Z; Liu X; Dong L; Li T; Chen H; Li J; He D; Lu X; Huang A; Tao Y; Wang Y; Zhang Z; Wei W; Li X; Zeng X
    Clin Rheumatol; 2022 Mar; 41(3):731-739. PubMed ID: 34709497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.
    Fleischmann RM; Alvarez DF; Bock AE; Cronenberger C; Vranic I; Zhang W; Alten R
    Arthritis Res Ther; 2021 Sep; 23(1):248. PubMed ID: 34563243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
    Bao C; Huang F; Khan MA; Fei K; Wu Z; Han C; Hsia EC
    Rheumatology (Oxford); 2014 Sep; 53(9):1654-63. PubMed ID: 24729398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
    van der Heijde D; Cheng-Chung Wei J; Dougados M; Mease P; Deodhar A; Maksymowych WP; Van den Bosch F; Sieper J; Tomita T; Landewé R; Zhao F; Krishnan E; Adams DH; Pangallo B; Carlier H;
    Lancet; 2018 Dec; 392(10163):2441-2451. PubMed ID: 30360964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
    Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study.
    Kay J; Jaworski J; Wojciechowski R; Wiland P; Dudek A; Krogulec M; Jeka S; Zielinska A; Trefler J; Bartnicka-Maslowska K; Krajewska-Wlodarczyk M; Klimiuk PA; Lee SJ; Bae YJ; Yang GE; Yoo JK; Furst DE; Keystone E
    Arthritis Res Ther; 2021 Feb; 23(1):51. PubMed ID: 33546755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.
    Pavelka K; Kivitz A; Dokoupilova E; Blanco R; Maradiaga M; Tahir H; Pricop L; Andersson M; Readie A; Porter B
    Arthritis Res Ther; 2017 Dec; 19(1):285. PubMed ID: 29273067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.
    Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J
    Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.
    Cohen S; Genovese MC; Choy E; Perez-Ruiz F; Matsumoto A; Pavelka K; Pablos JL; Rizzo W; Hrycaj P; Zhang N; Shergy W; Kaur P
    Ann Rheum Dis; 2017 Oct; 76(10):1679-1687. PubMed ID: 28584187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.